Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Experimental design

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Experimental design. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2015-005208-26 Sponsor Protocol Number: P13/12 Start Date*: 2016-02-22
    Sponsor Name:Centre Hospitalier de Versailles
    Full Title: CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITHOUT ACHIEVIN...
    Medical condition: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10058246 Chronic myelogenous leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-000790-38 Sponsor Protocol Number: CRSV 604A 2203 Start Date*: 2008-07-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of oral RSV604 in healthy adults experimentally infected with respiratory syncytial virus
    Medical condition: infection with respiratory syncytial virus
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-010739-42 Sponsor Protocol Number: H6D-MC-LVID Start Date*: 2009-10-01
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men with Signs ...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) NL (Completed) BE (Completed) AT (Completed) IT (Completed) FR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002781-21 Sponsor Protocol Number: CO11/9730 Start Date*: 2012-02-02
    Sponsor Name:Leeds Teaching Hospitals
    Full Title: A clinical study to evaluate the biological effects of administering rimantadine in patients with hepatitis C virus (HCV) infection alongside standard combination therapy with pegylated interferon ...
    Medical condition: Hepatitis C Virus infection - genotype 1. Genotype 1 is least responsive to current treatment and is the focus of this study. HCV can cause severe liver damage - this study will only recruit those ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000220-18 Sponsor Protocol Number: C.2524.0472.01 Start Date*: 2013-03-25
    Sponsor Name:University of Amsterdam
    Full Title: Effects of melatonin treatment, light therapy, and sleep improvement on psychosocial, cognitive, and behavioural outcomes in children with Delayed Sleep Phase Syndrome and their parents
    Medical condition: Delayed Sleep Phase Syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002485-31 Sponsor Protocol Number: OPIP Start Date*: 2017-01-31
    Sponsor Name:University Medical Center Groningen
    Full Title: Optimisation of [68Ga] PSMA-11 PET/CT Imaging Protocol for localizing primary prostate cancer prior to radical prostatectomy
    Medical condition: Primary localised prostate cancer, in men who opt for active treatment in the form of a radical prostatectomy
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001385-11 Sponsor Protocol Number: PrEP_COVID_19 Start Date*: 2020-03-28
    Sponsor Name:Plan Nacional Sobre SIDA
    Full Title: Prevention of SARS-CoV-2 (COVID-19) through Pre-Exposure Prophylaxis with Tenofovir disoproxil/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial controlled wit...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004321-15 Sponsor Protocol Number: H6D-MC-LVHK(b) Start Date*: 2007-12-14
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign P...
    Medical condition: Effects on urodynamic parameters in men with benign prostatic hyperplasia (also referred to as BPH-LUTS [lower urinary tract symptoms]) with and without urodynamic evidence of bladder outlet obstru...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002841-21 Sponsor Protocol Number: H6D-MC-LVHJ(a) Start Date*: 2008-10-28
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of B...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005347-14 Sponsor Protocol Number: H2020/PHRC-N/2014/GB-01 Start Date*: 2016-08-25
    Sponsor Name:CHU DE NIMES
    Full Title: Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients: A randomized, double-blind, pla...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-005009-30 Sponsor Protocol Number: Start Date*: 2016-05-04
    Sponsor Name:Gloucestershire Hospitals NHS Foundation Trust and
    Full Title: An open label, randomised controlled feasibility pilot study to evaluate whether nasal fentanyl alone and in combination with buccal midazolam give better symptom control to dying patients when com...
    Medical condition: Adult hospice in-patients with terminal cancer who are thought to be in the last 1 - 2 weeks of life
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10059513 Palliative care PT
    20.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020604-29 Sponsor Protocol Number: H6D-CR-LVIW(a), Addendum 1 u.4 Start Date*: 2010-11-05
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 3b,randomized,double-blind,placebo-controlled parallel-design study to evaluate the efficacy and safety of tadalafil coadministered with finasteride for 6 months in men with lower urinary ...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) FR (Completed) BE (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-002261-37 Sponsor Protocol Number: OHB103755 Start Date*: 2005-08-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of Radafaxine Extended-Release (100-140mg/day) Com...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-001958-27 Sponsor Protocol Number: H6D-MC-LVHG Start Date*: 2006-07-13
    Sponsor Name:Lilly ICOS LLC
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men ...
    Medical condition: Primary treatment of the signs and symptoms of benign prostatic hyperplasia in men (also referred to as BPH-LUTS [lower urinary tract symptoms]). BPH-LUTS include urinary frequency, urgency, interm...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022365-10 Sponsor Protocol Number: ARQ197-A-U302 Start Date*: 2011-02-11
    Sponsor Name:Daiichi Sankyo Development Limited
    Full Title: A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects with Locally Advanced or Metastatic, Non-Squam...
    Medical condition: Non-squamous, non–small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029514 Non-small cell lung cancer NOS LLT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed) ES (Completed) IT (Completed) SE (Completed) GB (Completed) DK (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007057-12 Sponsor Protocol Number: ML21846 Start Date*: 2009-04-06
    Sponsor Name:ROCHE
    Full Title: A Randomized open label study of the effect of first line combination treatment with Avastin (bevacizumab) plus paclitaxel and gemcitabine Compared With Avastin (bevacizumab) plus paclitaxel on...
    Medical condition: Metastatic breast cancer, HER2-negative patients who have not received prior chemotherapy for mBC
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006285 LLT
    9.1 10055113 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005723-33 Sponsor Protocol Number: amantadineSCEDI. Start Date*: 2015-03-27
    Sponsor Name:GGZ Oost Brabant
    Full Title: Efficacy of amantadine on behavioural and emotional problems and impairment of executive functioning due to acquired brain injury to the frontal lobes: a series of single case experimental design s...
    Medical condition: behavioural and emotional problems and impairment of executive functioning due to acquired brain injury to the frontal lobes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001356-37 Sponsor Protocol Number: NSGO-CC-0304 Start Date*: 2004-09-10
    Sponsor Name:Nordic Society for Gynecological Cancer
    Full Title: Phase I-II-III studies of Cisplatin and Combretastatin (CA4P) in recurrent or advanced servical cancer
    Medical condition: Metastatic or recurrent cervical cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003610-25 Sponsor Protocol Number: CT-MT001-2-2015-1 Start Date*: 2015-12-09
    Sponsor Name:Myelo Therapeutics GmbH
    Full Title: A randomised, double-blind, placebo-controlled, parallel-design, multi-centre study to investigate the efficacy to reduce chemotherapy-induced neutropenia (CIN), effects on the haematopoietic syste...
    Medical condition: Chemotherapy-induced neutropenia (CIN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10072806 Chemotherapy toxicity attenuation PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003498-41 Sponsor Protocol Number: D-Fampr Start Date*: 2015-09-22
    Sponsor Name:Medical University of Vienna
    Full Title: Effects of dalfampridine on mobility in the context of daily life
    Medical condition: Motor behaviour and cognition in multiple sclerosis patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 09:56:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA